Detalhe da pesquisa
1.
The PD-L1/4-1BB Bispecific Antibody-Anticalin Fusion Protein PRS-344/S095012 Elicits Strong T-Cell Stimulation in a Tumor-Localized Manner.
Clin Cancer Res
; 28(15): 3387-3399, 2022 08 02.
Artigo
Inglês
| MEDLINE | ID: mdl-35121624
2.
Effects of HER Family-targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer.
Clin Cancer Res
; 27(3): 807-818, 2021 02 01.
Artigo
Inglês
| MEDLINE | ID: mdl-33122343
3.
Acquired Resistance to Antibody-Drug Conjugates.
Cancers (Basel)
; 11(3)2019 Mar 20.
Artigo
Inglês
| MEDLINE | ID: mdl-30897808
4.
Translation and evaluation of a pre-clinical 5-protein response prediction signature in a breast cancer phase Ib clinical trial.
PLoS One
; 14(3): e0213892, 2019.
Artigo
Inglês
| MEDLINE | ID: mdl-30897176
5.
DuoMab: a novel CrossMab-based IgG-derived antibody format for enhanced antibody-dependent cell-mediated cytotoxicity.
MAbs
; 11(8): 1402-1414, 2019.
Artigo
Inglês
| MEDLINE | ID: mdl-31526159
6.
Combining Local Immunotoxins Targeting Mesothelin with CTLA-4 Blockade Synergistically Eradicates Murine Cancer by Promoting Anticancer Immunity.
Cancer Immunol Res
; 5(8): 685-694, 2017 08.
Artigo
Inglês
| MEDLINE | ID: mdl-28674083
7.
Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer.
PLoS One
; 12(5): e0177331, 2017.
Artigo
Inglês
| MEDLINE | ID: mdl-28493933
8.
Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity.
Clin Cancer Res
; 23(18): 5406-5415, 2017 Sep 15.
Artigo
Inglês
| MEDLINE | ID: mdl-28600476
9.
The 1.1 A resolution crystal structure of the p130cas SH3 domain and ramifications for ligand selectivity.
J Mol Biol
; 347(5): 1005-14, 2005 Apr 15.
Artigo
Inglês
| MEDLINE | ID: mdl-15784259
10.
Characterization of a re-engineered, mesothelin-targeted Pseudomonas exotoxin fusion protein for lung cancer therapy.
Mol Oncol
; 10(8): 1317-29, 2016 10.
Artigo
Inglês
| MEDLINE | ID: mdl-27507537
11.
First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors.
Clin Cancer Res
; 22(4): 877-85, 2016 Feb 15.
Artigo
Inglês
| MEDLINE | ID: mdl-26463709
12.
Deciphering the stepwise binding mode of HRG1ß to HER3 by surface plasmon resonance and interaction map.
PLoS One
; 10(2): e0116870, 2015.
Artigo
Inglês
| MEDLINE | ID: mdl-25658697
13.
Preclinical pharmacokinetics, pharmacodynamics, and efficacy of RG7116: a novel humanized, glycoengineered anti-HER3 antibody.
Cancer Chemother Pharmacol
; 75(4): 837-50, 2015 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-25702049
14.
Development of bispecific molecules for the in situ detection of protein-protein interactions and protein phosphorylation.
Chem Biol
; 21(3): 357-68, 2014 Mar 20.
Artigo
Inglês
| MEDLINE | ID: mdl-24529991
15.
ImmunoPET and biodistribution with human epidermal growth factor receptor 3 targeting antibody 89Zr-RG7116.
MAbs
; 6(4): 1051-8, 2014.
Artigo
Inglês
| MEDLINE | ID: mdl-24870719
16.
Antibody mediated CDCP1 degradation as mode of action for cancer targeted therapy.
Mol Oncol
; 7(6): 1142-51, 2013 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-24055141
17.
GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab.
Clin Cancer Res
; 19(5): 1126-38, 2013 Mar 01.
Artigo
Inglês
| MEDLINE | ID: mdl-23209031
18.
RG7116, a therapeutic antibody that binds the inactive HER3 receptor and is optimized for immune effector activation.
Cancer Res
; 73(16): 5183-94, 2013 Aug 15.
Artigo
Inglês
| MEDLINE | ID: mdl-23780344
19.
Structural requirements for cub domain containing protein 1 (CDCP1) and Src dependent cell transformation.
PLoS One
; 7(12): e53050, 2012.
Artigo
Inglês
| MEDLINE | ID: mdl-23300860
20.
Bispecific antibody derivatives with restricted binding functionalities that are activated by proteolytic processing.
Protein Eng Des Sel
; 25(10): 571-80, 2012 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-22976197